No Data
No Data
No Data
No Data
No Data
Merck's First-quarter Results Beat Expectations Amid Healthy Vaccine-sales Growth
Drugmaker boosts full-year sales and profit outlook
MarketWatchApr 25 06:53 ET · Earnings
Earnings Call Summary | Merck & Co(MRK.US) Q1 2024 Earnings Conference
The following is a summary of the Merck & Co., Inc. (MRK) Q1 2024 Earnings Call Transcript:Financial Performance:Total company revenues for Q1 2024 were $15.8 billion, up 9% or 12% excluding foreign e
moomoo AI4minutes ago · Conference Call
Express News | NYSE Order Imbalance 460766.0 Shares on Sell Side
Reuters15:50 ET
Express News | Merck & Co Inc: Updated Initial Commitment to Supply a Total of 115 Mln Doses of Hpv Vaccine Through 2025, an Increase of Approximately 20 Mln Doses
Reuters14:46 ET
Express News | Merck & Co Inc: Remains Committed to Providing a Reliable Supply & Equitable Access to Our Vaccines for People Who Use Them Around the World
Reuters14:46 ET
Express News | Merck & Co Inc - We Expect to Supply Sufficient Quantities of Hpv Vaccines to Meet Anticipated Demand for All of Our Hpv Vaccines in 2025
Reuters14:46 ET
Strike freedom : Don’t have akebia?
MeltyyOP Strike freedom: the first of the post
Strike freedom MeltyyOP: I mean in the April calendar
Srav Reddy : Wonder why $Akebia Therapeutics (AKBA.US)$ dropped after PDUFA
No Data
No Data